Impact Factor 6.429

The 5th most cited journal in Immunology

Review ARTICLE Provisionally accepted The full-text will be published soon. Notify me

Front. Immunol. | doi: 10.3389/fimmu.2018.00414

Alteration of the antitumor immune response by cancer-associated fibroblasts

Linda ZIANI1,  Salem Chouaib1 and  Jerome THIERY1*
  • 1Institut National de la Santé et de la Recherche Médicale (INSERM), France

Among cells present in the tumor microenvironment, activated fibroblasts termed cancer-associated fibroblasts (CAFs), play a critical role in the complex process of tumor-stroma interaction. CAFs, one of the prominent stromal cell populations in most types of human carcinomas, have been involved in tumor growth, angiogenesis, cancer stemness, extracellular matrix remodeling, tissue invasion, metastasis and even chemoresistance. During the past decade, these activated tumor-associated fibroblasts have also been involved in the modulation of the anti-tumor immune response on various levels. In this review, we describe our current understanding of how CAFs accomplish this task as well as their potential therapeutic implications.

Keywords: Cancer, Tumor Microenvironment, cancer-associated fibroblasts, immune suppression, Immunotherapy

Received: 13 Nov 2017; Accepted: 14 Feb 2018.

Edited by:

Khashayarsha Khazaie, Mayo Clinic College of Medicine & Science, Mayo Clinic, United States

Reviewed by:

Alessandro Poggi, Dipartimento delle Terapie Oncologiche Integrate, Ospedale Policlinico San Martino, Italy
Fabian Benencia, Ohio University, United States  

Copyright: © 2018 ZIANI, Chouaib and THIERY. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Dr. Jerome THIERY, Institut National de la Santé et de la Recherche Médicale (INSERM), Paris, France,